These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6765531)

  • 1. Decrease of circulating insulin antibodies in two patients treated with continuous subcutaneous infusion of human insulin (recombinant DNA).
    Spijker AJ; Poortman J; Thijssen JH; Erkelens DW
    Diabetes Care; 1982; 5 Suppl 2():171-4. PubMed ID: 6765531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe lipoatrophy with human insulin: successfully treated by CSII.
    Chantelau E; Reuter M; Schotes S; Starke AA
    Diabet Med; 1993 Jul; 10(6):580-1. PubMed ID: 8365099
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy.
    Chiasson JL; Ducros F; Poliquin-Hamet M; Lopez D; Lecavalier L; Hamet P
    Diabetes Care; 1984; 7(4):331-7. PubMed ID: 6381006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects.
    Fireman P; Fineberg SE; Galloway JA
    Diabetes Care; 1982; 5 Suppl 2():119-25. PubMed ID: 6765521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment.
    Dahl-Jørgensen K; Torjesen P; Hanssen KF; Sandvik L; Aagenaes O
    Diabetes; 1987 Jan; 36(1):1-5. PubMed ID: 3539672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion.
    Walter HM; Timmler R; Mehnert H
    Diabetes Res; 1990 Feb; 13(2):75-7. PubMed ID: 2091873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.
    Sahin SB; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
    Acta Diabetol; 2010 Dec; 47(4):325-30. PubMed ID: 20842389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma immunoreactive somatostatin response to arginine after glycemic control with continuous subcutaneous insulin infusion in type I diabetics.
    Kobayashi T; Sawano S; Itoh T; Kosaka K
    Diabetes Care; 1987; 10(3):286-92. PubMed ID: 2885161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
    Potti LG; Haines ST
    J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA).
    Velcovsky HG; Federlin KF
    Diabetes Care; 1982; 5 Suppl 2():126-8. PubMed ID: 6765522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
    Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
    Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Scheen AJ; Henrivaux P; Jandrain B; Lefebvre PJ
    Diabetes Care; 1986; 9(6):673-4. PubMed ID: 3803158
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus.
    Kwai N; Arnold R; Poynten AM; Lin CS; Kiernan MC; Krishnan AV
    Diabetes Metab Res Rev; 2015 Feb; 31(2):175-82. PubMed ID: 25066412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis.
    Rabbone I; Barbetti F; Marigliano M; Bonfanti R; Piccinno E; Ortolani F; Ignaccolo G; Maffeis C; Confetto S; Cerutti F; Zanfardino A; Iafusco D
    Acta Diabetol; 2016 Aug; 53(4):559-65. PubMed ID: 26831749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Habitual physical activity in adult IDDM patients. A study with portable motion meters.
    Chantelau E; Wirth R
    Diabetes Care; 1992 Nov; 15(11):1727-31. PubMed ID: 1468308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes.
    Alemzadeh R; Parton EA; Holzum MK
    Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.